Page last updated: 2024-08-24

plerixafor and diprotin a

plerixafor has been researched along with diprotin a in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Broxmeyer, HE; Christopherson, KW; Hangoc, G; Mantel, CR1
Assmann, G; Brunner, S; Fischer, R; Franz, WM; Gröbner, M; Hacker, M; Huber, B; Krieg, L; Mueller-Hoecker, J; Rischpler, C; Theiss, HD; Vallaster, M; Vanchev, Y; Wollenweber, T; Zaruba, MM1

Other Studies

2 other study(ies) available for plerixafor and diprotin a

ArticleYear
Modulation of hematopoietic stem cell homing and engraftment by CD26.
    Science (New York, N.Y.), 2004, Aug-13, Volume: 305, Issue:5686

    Topics: Animals; Benzylamines; Cell Cycle; Cell Movement; Cell Survival; Chemokine CXCL12; Chemokines, CXC; Chemotaxis; Cyclams; Dipeptidyl Peptidase 4; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Mice; Mice, Inbred C57BL; Oligopeptides; Receptors, CXCR4

2004
Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis.
    Stem cell research, 2011, Volume: 7, Issue:3

    Topics: Animals; Antigens, CD34; Benzylamines; Chemokine CXCL12; Cyclams; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Heart Function Tests; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Leukocyte Common Antigens; Mice; Models, Biological; Myocardial Infarction; Neovascularization, Physiologic; Oligopeptides; Perfusion; Proto-Oncogene Proteins c-kit; Receptors, CXCR4; Stem Cell Transplantation; Survival Analysis

2011